Neither company owns a mechanism. Both dispense the same drug classes, so the difference is which molecules each stocks and whether the version supplied is the one that was studied. Ro carries approved brand products with registration trials behind them. Mochi carries those molecules too, plus compounded versions and older oral agents working through unrelated pathways.
Three mechanisms, not one
The class splits cleanly. Semaglutide and liraglutide are peptide agonists at the GLP-1 receptor, slowing gastric emptying and acting on central appetite signaling. Tirzepatide adds agonism at the receptor for glucose-dependent insulinotropic polypeptide, giving it two incretin targets rather than one. Orforglipron is different again: a small molecule rather than a peptide, which is why it exists as a daily tablet instead of a weekly injection. A 2024 review sets out how the single and dual receptor approaches diverge pharmacologically.
Ro’s catalog spans all three: Wegovy in pen and pill form, Zepbound as a pen and a KwikPen, Ozempic, Saxenda and the orforglipron tablet Foundayo. Mochi’s stated prescribing list covers tirzepatide, semaglutide and liraglutide too, then extends into different pharmacology with topiramate, bupropion, naltrexone and orlistat. Those older agents act on appetite and absorption through mechanisms unconnected to incretin biology, with smaller expected effect sizes.
What the trials measured, and what they did not
The evidence base belongs to molecules. In its registration trial, once-weekly semaglutide 2.4 mg produced a mean body weight change of roughly 15 percent over 68 weeks in adults with overweight or obesity. Tirzepatide, in a separate trial with its own population and a 72-week timeframe, produced roughly 21 percent at the highest dose. Those were two distinct studies and the figures indicate direction rather than a measured gap between the two drugs. A later retrospective analysis that compared the molecules directly reported greater average reduction with tirzepatide, which is a different kind of evidence from either registration trial and carries the limitations of its design.
Orforglipron has its own published trial in obesity treatment, and it is now an approved product rather than an investigational one. Its labeled use is weight reduction and long-term maintenance in adults with obesity, or with overweight plus at least one weight-related condition. Tirzepatide also carries a separate indication for moderate to severe obstructive sleep apnea in adults with obesity, supported by its own randomized trial rather than by the weight studies.
| Molecule | Mechanism | Form | Principal published evidence |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Weekly injection and daily tablet | 68-week randomized trial in overweight and obesity |
| Tirzepatide | Dual GIP and GLP-1 receptor agonist | Weekly injection | 72-week randomized obesity trial; separate sleep apnea trial |
| Liraglutide | GLP-1 receptor agonist | Daily injection | Older approved agent with its own weight management program |
| Orforglipron | Oral small-molecule GLP-1 receptor agonist | Daily tablet | Published obesity trial supporting a 2026 approval |
| Topiramate, bupropion, naltrexone, orlistat | Non-incretin appetite and absorption pathways | Oral | Older evidence base with smaller average effects |
| Compounded semaglutide or tirzepatide | Same target as the brand molecule | Injection prepared by a pharmacy | No trial attaches to the specific preparation |
Where the evidence stops transferring
This is the part that decides how much a trial result should influence a purchase. A registration trial studies a specific product made a specific way, at specific strengths, with the manufacturing under review. A compounded preparation of the same molecule has not been through that review. The FDA does not evaluate compounded drugs for safety, effectiveness or quality before they reach patients, and Mochi prints that statement on the page where its compounded products are listed. The molecule is the same; the evidence for the finished item is not the same evidence.
That gap is not theoretical. A pharmacovigilance analysis of adverse event reports involving compounded GLP-1 receptor agonists has been published, and a poison control center case series documented administration errors with compounded semaglutide arising from unfamiliar concentrations and syringe markings. Neither finding says compounded care is unsafe as a category, and licensed pharmacies operate under a defined statutory framework. They do say that the product a patient receives is the thing being evaluated, not the molecule in the abstract.
For a reader weighing the two, this converts into one plain check. If the pathway is compounded, the trial percentages quoted in advertising describe a related product rather than the one arriving in the box. Programs that print the pathway next to the price make that easy to see. One competitor-written comparison of these two companies argues the same point about pathway disclosure, and the provider behind it lists a flat monthly figure for compounded semaglutide in the same place as its regulatory status, as do Henry Meds and Eden.
Expected results, and who is doing the expecting
Both companies publish outcome figures, and neither figure is a trial result. Ro states an average one-year loss of 11 to 20 percent, referencing studies of the highest doses in non-diabetic adults with obesity or overweight plus a weight-related condition, alongside diet and exercise. It also discloses that its featured members were paid for their testimonials and that certain percentage claims come from a survey of its own members. Mochi states that members in its medication-based programs lose approximately 15 percent of their weight on average.
Self-reported program averages are not comparable across companies. They rest on different denominators, different follow-up windows and different rules about who counts as a member. What can be compared is the underlying molecule and the dose actually reached, because a patient who stops at a low maintenance strength is not on the regimen the trials studied. A UK cohort study of GLP-1 users found that a substantial proportion never reached the higher doses, which is one reason real-world averages sit below trial figures at every provider.
The same receptor science and the same video-visit-and-pharmacy model now sit behind more than weight loss. Ro and Hims and Hers apply that pattern across men’s health, and a provider such as HealthRX lists ED treatment beside its metabolic offerings. The checks this piece applies to a GLP-1 purchase, what molecule is being supplied, what published evidence stands behind it, and whether the item shipped is the one that was actually studied, carry over to any category a buyer shops through the same channel.
Frequently asked questions
Does the dual-receptor drug always outperform the single-receptor one?
On average across the published work it produces larger reductions, but the two registration trials were separate studies with different populations, so the difference between their headline numbers is not a measured margin. Individual response varies widely, and tolerability often decides which molecule a patient can actually stay on.
Do the oral tablets work through a different mechanism?
The semaglutide tablet is the same peptide in an oral formulation, so the mechanism is unchanged. Orforglipron is genuinely different, a small molecule rather than a peptide, which is what allows straightforward daily oral dosing. Both reach the same receptor by different chemistry and different absorption routes.
Should a compounded product be expected to match trial results?
There is no published trial of the specific preparation, so the honest answer is that nobody knows the finished product’s performance in a controlled setting. The molecule has strong evidence behind it. Extending that evidence to an unreviewed preparation is an assumption, and it should be stated as one.
Why do the older oral agents still appear on prescribing lists?
Because they suit cases the incretin drugs do not. Cost, injection aversion, tolerability and comorbidity all push prescribers toward alternatives, and some of these agents have useful secondary effects. Their average weight reduction is smaller, which is a trade a prescriber and patient can reasonably choose to make.
How much weight should company-reported averages carry?
Very little in a purchase decision. They are marketing figures produced from self-selected populations without a control group, published by the seller. Labeled indications, the molecule, the dose reached and the price at that dose are all more informative and all independently checkable.
